Park, So Youn <br/><br/>
Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription.  [electronic resource] 

 -  The Journal of pharmacology and experimental therapeutics  May 2009 
 - 571-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1521-0103 
<br/><br/><label>Standard No.: </label>10.1124/jpet.108.146456  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>3T3-L1 Cells<br/>Adiponectin--blood<br/>Adipose Tissue--drug effects<br/>Animals<br/>Biomarkers--analysis<br/>Blood Glucose--metabolism<br/>Body Weight--drug effects<br/>Cilostazol<br/>Diabetes Mellitus, Experimental--drug therapy<br/>Diabetes Mellitus, Type 2--drug therapy<br/>Fibroblasts--drug effects<br/>Gene Expression--drug effects<br/>Glucose Transporter Type 4--biosynthesis<br/>Insulin--blood<br/>Male<br/>Mice<br/>Mice, Inbred C57BL<br/>PPAR gamma--biosynthesis<br/>Phosphodiesterase Inhibitors--administration & dosage<br/>Receptors, Leptin--deficiency<br/>Tetrazoles--administration & dosage<br/>Transcriptional Activation--drug effects<br/>Triglycerides--blood<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors<br/>Vascular Cell Adhesion Molecule-1--biosynthesis